News

Today’s announcement marks the first and only FDA approval of a Regimen of two Immuno-Oncology agents in cancer. This indication is approved under accelerated approval based on tumor

In 2005, Merck bought the rights to Kuvan and Peg-Pal, another PKU treatment, outside the US and Japan. BioMarin will pay Merck €340m for Kuvan and about €185m

The move marks first product opt-in since the companies formed an alliance in January last year to speed up and expand the development and commercialization of RNAi therapeutics

The document provides guidance for the conduct of robust analyses to facilitate and speed up the development of new antibiotics, in particular those targeting multi-drug resistant bacteria. Comments

The results were presented at the European Respiratory Society (ERS) International Congress 2015, and confirm that OFEV has a long-term effect on slowing disease progression and a manageable

The company said the variant is for the patients not taking chronic inhaled aminoglycoside antibiotics. If approved, Translarna would be the first oral protein restoration treatment that targets

In addition, GSK sold its marketed oncology portfolio to Novartis India. The transaction follows a worldwide transaction between their parent firms GSK and Novartis, which was completed earlier

APP-111 showed efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer. In preclinical studies, the drug appeared to have less peripheral

Under a collaboration and option agreement signed in June 2012, Liquidia was entitled to receive an upfront payment including cash and equity, R&D funding, and possible development milestones